Nafamostat mesylate versus low-molecular-weight heparin during continuous renal replacement therapy in critically Ill adults: a single-center retrospective cohort study

Xianguo Zeng, Yutong Xiao, Chaoqun Zhang, Yide Li, Yongjun Liu, Liang Luo

Open source

DOI
10.1186/s12882-026-05351-9
Published
2026-09-07
Container
BMC Nephrology
Publisher
Springer Science and Business Media LLC
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1186/s12882-026-05351-9,
  title = {Nafamostat mesylate versus low-molecular-weight heparin during continuous renal replacement therapy in critically Ill adults: a single-center retrospective cohort study},
  author = {Xianguo Zeng and Yutong Xiao and Chaoqun Zhang and Yide Li and Yongjun Liu and Liang Luo},
  year = {2026},
  journal = {BMC Nephrology},
  doi = {10.1186/s12882-026-05351-9},
  url = {https://doi.org/10.1186/s12882-026-05351-9}
}

RIS

TY  - JOUR
TI  - Nafamostat mesylate versus low-molecular-weight heparin during continuous renal replacement therapy in critically Ill adults: a single-center retrospective cohort study
AU  - Xianguo Zeng
AU  - Yutong Xiao
AU  - Chaoqun Zhang
AU  - Yide Li
AU  - Yongjun Liu
AU  - Liang Luo
PY  - 2026
JO  - BMC Nephrology
DO  - 10.1186/s12882-026-05351-9
UR  - https://doi.org/10.1186/s12882-026-05351-9
ER  - 

APA

Zeng, X., Xiao, Y., Zhang, C., Li, Y., Liu, Y., & Luo, L. (2026). Nafamostat mesylate versus low-molecular-weight heparin during continuous renal replacement therapy in critically Ill adults: a single-center retrospective cohort study. BMC Nephrology. https://doi.org/10.1186/s12882-026-05351-9

Source records